肾型谷氨酰胺酶（GLS1）是一个关键酶，控制着谷氨酰胺水解成谷氨酸以解决肿瘤细胞“谷氨酰胺成瘾”，在支持癌细胞增长和增殖方面发挥着核心作用。因此，抑制GLS1作为一种新型肿瘤治疗策略具有极大的兴趣。本综述介绍了涉及GLS1抑制剂的最新专利（2019至今），这些抑制剂主要关注于它们的化学结构、分子机制、药代动力学特性和潜在临床应用。尽管经过了大量的努力，但寻找强效的GLS1抑制剂并未开发出适用于治疗的化合物。在这一时期，大部分的最新专利和文献都集中在GLS1抑制剂IPN60090和DRP104上，它们已进入临床试验阶段。虽然此期间的其他专利披露并没有带来任何药物候选者，但临床更新将会提示这些抑制剂作为单独或组合干预的有前途的治疗药物。

Kidney-type glutaminase (GLS1), a key enzyme controlling the hydrolysis of glutamine to glutamate to resolve the 'glutamine addiction' of cancer cells, has been shown to play a central role in supporting cancer growth and proliferation. Therefore, the inhibition of GLS1 as a novel cancer treating strategy is of great interest.This review covers recent patents (2019-present) involving GLS1 inhibitors, which are mostly focused on their chemical structures, molecular mechanisms of action, pharmacokinetic properties, and potential clinical applications.Currently, despite significant efforts, the search for potent GLS1 inhibitors has not resulted in the development of compounds for therapeutic applications. Most recent patents and literature focus on GLS1 inhibitors IPN60090 and DRP104, which have entered clinical trials. While other patent disclosures during this period have not generated any drug candidates, the clinical update will inform the potential of these inhibitors as promising therapeutic agents either as single or as combination interventions.